Therapy Stock Review: Outstanding 10.96% Weekly Gain $BIIB, $URGN, $ALLO
Thriving in Therapy: A Deeper Look into the Biotech and Pharmaceutical Theme
Overview of the Therapy Theme
Theme Therapy +10.96% - 1W change
Swing trader: Long-Short Equity Strategy (TA&FA) Annualized Return + 64% and Swing trader: High Capitalization (TA) Annualized Return + 7%
As the world grapples with various health challenges, the need for innovative therapeutic solutions cannot be overstated. In the financial market, the Therapy theme represents an intriguing investment opportunity. This theme focuses on biotech and pharmaceutical companies that discover, develop, manufacture, and deliver therapies for treating various diseases and disorders. The industry is part of the overall healthcare field but has a specific focus on the development of treatments to cure or prevent diseases.
This theme includes tickers such as $ACRS, $ALLO, $ALNY, $ARVN, $BIIB, $BPMC, $EVLO, $INMB, $KRYS, $LIVN, $OCUL, $URGN, $USPH, and $VKTX. These companies are diverse in their operations but united by their commitment to developing and delivering life-saving therapies.
Market Capitalization Analysis
These therapy-themed companies boast a collective average market capitalization of $5.8B, with individual valuations ranging from $153.8M to a whopping $39.1B. Leading the pack is Biogen ($BIIB) with the highest valuation of $39.1B, while Immune Bio Inc. ($INMB) trails with the smallest market cap at $153.8M.
A Peek into Performance: Allogene Therapeutics ($ALLO), UroGen Pharma ($URGN), and Biogen ($BIIB)
Allogene Therapeutics ($ALLO)
Allogene Therapeutics has demonstrated some volatility in its performance. For instance, the company experienced a notable downtrend with a -6.62% decrease on July 25, 2023, and a -8.49% fall on July 15, 2023. However, the company also showed resilience with a +9.61% jump on July 7, 2023, indicating an uptrend reversal. This fluctuation in performance demonstrates the dynamic nature of the biotech industry.
UroGen Pharma ($URGN)
UroGen Pharma, on the other hand, has been a high flyer in the Therapy theme, exhibiting the highest price growth at 129.64%. This significant growth reflects the company's innovative approach to developing and commercializing therapies designed to change the standard of care for urological pathologies.
Biogen ($BIIB)
Biogen, the heavyweight in this theme, demonstrates why it commands such a massive market capitalization. With a valuation of $39.1B, the company continues to be a major player in the industry, providing a wide array of therapies for diseases such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, among others.
Volume Fluctuation Analysis
The average weekly volume growth across all stocks in the group stands at 95.5%. Allogene Therapeutics ($ALLO) experienced a record-breaking daily growth of 1,009% of the 65-Day Volume Moving Average on June 24, 2023. On May 26, 2023, US Physical Therapy ($USPH) had a similar record-breaking daily growth of 1,369% of the 65-Day Volume Moving Average. Krystal Biotech ($KRYS) also experienced a significant two-day consecutive volume increase, resulting in a daily growth of 178% of the 65-Day Volume Moving Average on May 25, 2023. These volume fluctuations provide an insightful look into investor interest and trading activity within the Therapy theme.
Fundamental Analysis Ratings
Fundamental analysis ratings provide another valuable perspective on the health and potential of companies within this theme. On average, companies in this theme have a Valuation Rating of 72, P/E Growth Rating of 88, a Price Growth Rating of 51, an SMR Rating of 91, and a Profit Risk Rating of 83. The Seasonality Score stands at 15. These scores indicate the overall health and potential for growth of these companies, offering another piece of the investment decision puzzle.
The Therapy theme offers a myriad of opportunities for investors who are passionate about healthcare and the development of novel therapeutic treatments. The performance of the companies under this theme not only shows their potential for growth but also the crucial role they play in improving global health outcomes.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
BIIB saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for BIIB moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 57 similar instances where the indicator exited the overbought zone. In 40 of the 57 cases the stock moved lower. This puts the odds of a downward move at 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BIIB as a result. In 55 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on October 13, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in 36 of 61 cases over the following month. The odds of a continued upward trend are 59%.
Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 164 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
The Aroon Indicator entered an Uptrend today. In 116 of 180 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.793) is normal, around the industry mean (19.199). P/E Ratio (40.620) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). BIIB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor
Advertisement